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Phosphorylated tau (p-tau) is the principal component of neuroﬁbrillary tangles, a pathological hall-
mark, and likely plays a neurotoxic role in tauopathies including Alzheimer’s disease (AD), progres-
sive supranuclear palsy (PSP), and corticobasal degeneration (CBD). We subjected brains from
autopsy cases of AD, PSP, and CBD to a variety of immunohistochemical, immunoblotting, and
pull-down assays. In this study, we show that excitatory amino acid transporter 2 (EAAT2) preferen-
tially interacted with phosphorylated tau and was localized in neuroﬁbrillary tangles in the brains
of such patients. These results strongly indicate that EAAT2 acts in tauopathy-related neurodegen-
eration, and abnormalities in glutamate transport play an important role in the pathogenesis of tau-
opathies.
Structured summary:
MINT-7148349, MINT-7148361:TAU (uniprotkb:P10636) physically interacts (MI:0914) with EAAT2 (uni-
protkb:P43004) by pull-down (MI:0096)
MINT-7148372, MINT-7148384:TAU (uniprotkb:P10636) physically interacts (MI:0914) with EAAT2 (uni-
protkb:P43004) by anti bait coimmunoprecipitation (MI:0006)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction mutations leading to diverse clinical phenotypes collectivelyTau is a microtubule-associated protein mainly expressed in
neurons where it plays a role in the assembly and stability of the
microtubule network. Tau is also strongly linked to several neuro-
degenerative disorders as the principle pathological component of
ﬁlamentous inclusions called neuroﬁbrillary tangles (NFTs) found
in the brains of Alzheimer’s disease (AD) patients and in a variety
of diseases collectively called ‘‘tauopathies”, including progressive
supranuclear palsy (PSP) and corticobasal degeneration (CBD) [1].
Although these diseases are sporadic, the tau gene can harborchemical Societies. Published by E
gressive supranuclear palsy;
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ri).grouped under frontotemporal dementia with parkinsonism linked
to chromosome 17 [2].
Phosphorylated tau (p-tau) has been identiﬁed as a major pro-
tein component of NFTs [3,4]. Considerable evidence supports that
p-tau represents the pathological entity in tauopathies, including
the observation that increased p-tau causes neuronal cell death
[5]. Because phosphorylation releases tau from microtubules and
tau in NFTs is phosphorylated, kinases have been viewed suspi-
ciously for a possible pathogenetic role. In vivo evidence for inter-
action with tau exists for cyclin-dependent kinase-5 (cdk5)/p25
and glycogen synthase kinase-3b (GSK-3b). Tau phosphorylation
by cdk5 in mice [6] and GSK-3b in ﬂies [7] can cause or accelerate
NFT formation in vivo with an attendant worsening of neurodegen-
eration. Moreover, as endogenous tau was phosphorylated, aggre-
gated tau accumulated, and neuroﬁbrillary pathology developed
progressively in these animals.
In light of such evidence, analyzing the molecular complex of p-
tau and mechanism of p-tau-induced cell death is important forlsevier B.V. All rights reserved.
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ies, we showed that CHIP and HSP27 interact with p-tau, decrease
its amounts, and protect against p-tau-induced neurotoxicity [8,9].
In this study, we provide evidence that excitatory amino acid
transporter 2 (EAAT2) is a molecular complex of p-tau. EAAT2 is
a glutamate transporter and its dysfunction is tightly linked to
neurodegenerative disorders [10]. We also demonstrate that
EAAT2 preferentially interacts with p-tau rather than dephospho-
rylated tau and is localized within NFTs of patients with AD, PSP,
and CBD.
2. Materials and methods
2.1. Antibodies
The EAAT2 polyclonal antibody, also known as HS5, which is an
antibody to the 20-mer sequence (TEGANNMPKQVEVRNHDSHL) at
the N-terminal domain of human EAAT2, was generated and char-
acterized as described previously [11]. The anti-tau antibodies
used included tau antibodies, anti-phosphorylated tau antibodies,
and anti-non-phosphorylated tau antibodies. The tau antibody
used was a monoclonal mouse tau antibody (Sigma, St. Louis,
MO, USA), which recognizes all tau isoforms. The anti-phosphory-
lated tau antibodies used included AT8 (Pierce, Rockford, IL, USA),
which recognizes phosphorylated S202 and T205 residues, and
PHF1 [12,13], which recognizes phosphorylated S396 and S404
residues. Tau 1 [14] was used as an anti-non-phosphorylated tau
antibody, which recognizes non-phosphorylated S199, S202, and
T205 residues. Rabbit anti-EAAT2 antibody H85 and goat anti-Table 1
Clinical data of all autopsied subjects.
Case Age Sex Postmortem delay (h)
Normal 1 66 Male 5
Normal 2 70 Female 2.5
Normal 3 81 Male 2.5
AD1 66 Male 3.5
AD2 72 Female 3
AD3 76 Male 5
AD4 81 Female 4.5
PSP1 69 Male 6.5
PSP2 85 Female 3.5
CBD1 61 Male 8
CBD2 81 Female 9
Fig. 1. Excitatory amino acid transporter 2 (EAAT2) interacts with phosphorylated tau. H
been phosphorylated by GSK-3b and Cdk5/p25. Eluates were separated by SDS–PAGE an
EAAT2. The peptide sequence (bold) obtained from the 62-kDa band was consistent witEAAT2 antibody N19 were obtained from Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, CA, USA.
2.2. In vitro phosphorylation
Active recombinant GSK-3b (Upstate Biotechnology, Lake Pla-
cid, NY, USA) and Cdk5/p25 (Cosmo Bio Co. Ltd., Tokyo, Japan) were
incubated in a reaction mixture containing 2 mM ATP, 20 mM
HEPES (pH 6.8), 10 mM MgCl2, and 10 mM MnCl2 with recombi-
nant His-tau (Sigma). Tau phosphorylation sites were conﬁrmed
by the phosphorylated tau-speciﬁc antibodies PHF1 (S396 and
S404) and AT8 (S202 and T205).
2.3. Brain tissue samples
Brain tissue was obtained by autopsy from four AD (AD1, 2, 3
and 4), two CBD (CBD1 and 2), two PSP (PSP1 and 2), and three nor-
mal cases (normal 1, 2 and 3). Autopsies were performed by
authorized pathologists to conﬁrm diagnosis or other clinical
imperatives. Informed consent was obtained from the next-of-kin
in all cases. Diagnoses were performed by viewing the pathological
sections. Age, sex, and postmortem delay are summarized
in Table 1.
2.4. Immunopuriﬁcation and immunoblotting
Immunopuriﬁcation, immunoblotting, and pull-down assays
were performed as described previously [8,9]. Temporal cortex
specimens (2 g) were homogenized in lysis buffer containing 1%
Triton-X 100 and sedimented at 20 000g for 1 h at 4 C. Superna-
tants were incubated with protein A/G (Pierce) bound to the tau
monoclonal antibody (Sigma) or HS5 for 2 h at 4 C. SDS buffer
(4) was added to lysates and immunoprecipitates. SDS–PAGE
and immunoblotting were performed as described previously
[11,12]. The intensity was analyzed using a chemiluminescence
image analyzer Las-1000 Plus (Fuji ﬁlm, Tokyo, Japan). The value
was compared to that of AD1.
2.5. Pull-down assays
Either His-tau or phosphorylated His-tau-coupled nickel beads
were added to human brain homogenates incubated at 4 C for
1 h with shaking. We added 4 SDS to release precipitated proteins
from the beads. The eluted fraction was transferred to a new tube
after centrifugation and 0.1 N Tris–HCl buffer (pH 8.5) was added.uman brain homogenates were passed over nickel beads coupled to His-tau that had
d stained with Coomassie brilliant blue (CBB) or immunoblotted with antibodies to
h the human EAAT2 protein sequence (NCB Accession # NP 004162).
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Immunohistochemical studies were performed as described
previously [13]. Sections (10-lm thick) of formalin-ﬁxed, paraf-
ﬁn-embedded tissue from the medial temporal cortex were incu-
bated with 70% formic acid for antigen activation followed by
immunostaining with EAAT2 antibodies. By confocal microscopy,Fig. 2. (A) Brain homogenates of the temporal cortex from four Alzheimer’s disease (AD),
three normal cases were immunoprecipitated with HS5 polyclonal EAAT2 or monoclo
polyclonal EAAT2 antibodies. (B) Quantitative analysis of immunoprecipitated tau and E
homogenates. Values are normalized to the value of AD1. Data are presented as mean SAT8 (Pierce), which speciﬁcally recognizes p-tau, was visualized
by a secondary antibody conjugated to Texas Red and EAAT2 by
a secondary antibody conjugated to FITC.
2.7. Extraction of sarkosyl-insoluble proteins
Sarkosyl-insoluble proteins were extracted from the temporal
cortex as described previously [14]. Extracts were divided intotwo progressive supranuclear palsy (PSP), two corticobasal degeneration (CBD), and
nal tau antibodies. Precipitates were analyzed by PHF1, monoclonal tau, or HS5
AAT2 levels standardized against the amount of protein detected in relevant crude
.D. (C) Analysis of antibody speciﬁcity for immunoprecipitation.
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syl-insoluble fractions.Fig. 3. Ability of EAAT2 to interact with phosphorylated tau (p-tau) was examined
by a pull-down assay in which human brain homogenates were passed over 20 lL
nickel beads coupled to His-phosphorylated tau or His-tau. Precipitated proteins
were analyzed by the EAAT2 antibody.3. Results
We sought to identify molecular complexes associated with tau
when it is phosphorylated at sites that are phosphorylated in AD
(Ser-202, Thr-205, Ser-396, and Ser-404). Human brain homoge-
nates were passed through an afﬁnity column with nickel beads
coupled to a recombinant four-repeat His-tau phosphorylated by
Cdk5/p25 and GSK-3b, and associated proteins were eluted with
1 M NaCl. Eluted proteins were separated by SDS–PAGE and sev-
eral bands were stained with Coomassie Brilliant Blue (CBB). A
62-kDa CBB band was identiﬁed by mass spectrometry that con-
tained the sequences MASTEGANNMP and CLEENLGIDK, which ex-
actly matched the human EAAT2 sequence (Fig. 1). The sequence
did not, however, match the human EAAT1, EAAT3, EAAT4, and
EAAT5 sequences. This 62-kDa molecule was also immunoreactive
to various anti-EAAT2 antibodies, including N19 (Santa Cruz Bio-
technology), H85 (Santa Cruz Biotechnology), and the rabbit poly-
clonal anti-EAAT2 antibody HS5 (Fig. 1).
To examine the interaction between EAAT2 and p-tau, we con-
ducted coimmunoprecipitation of homogenates from the frozen
temporal cortex obtained from 4 AD, 2 PSP, 2 CBD, and 3 normal
brains. We used HS5 for immunoprecipitation followed by immu-
noblotting with PHF1, a monoclonal antibody that recognizes path-
ological tau phosphorylated at residues Ser-396 and Ser-404, and a
monoclonal tau antibody that recognizes all tau isoforms (Fig. 2A).
Multiple tau bands of 30–60 kDa were recognized by the monoclo-
nal tau antibody in all cases, whereas p-tau bands were detected
only in crude extracts of AD, PSP, and CBD brains. As expected, only
faint bands were recognized by PHF1 in normal brains. P-tau
coprecipitated with the anti-EAAT2 antibody HS5 from AD, PSP,
and CBD brains but not from normal brains. Larger amounts of
tau coprecipitated with HS5 from AD, PSP, and CBD brains than
those from normal brains (Fig. 2B). Coprecipitates of the anti-
EAAT2 antibody were not stained with the tau1 antibody, which
only recognized dephosphorylated tau (data not shown). Reverse
coimmunoprecipitation experiments showed that larger amounts
of EAAT2 coprecipitated with the monoclonal tau antibodies from
AD, PSP, and CBD brains than those from normal brains. Thus, the
tau protein that immunoprecipitated with the EAAT2 antibody was
mainly p-tau. We performed immunoprecipitations in the absence
or presence of an antibody for immunoprecipitations for determin-
ing antibody speciﬁcity for immunoprecipitation. We did not de-
tect immunoreactivities in all immunoprecipitation experiments
conducted in the absence of antibodies for immunoprecipitates
(Fig. 2C).
To further determine the speciﬁcity of interaction between p-
tau and EAAT2, we incubated nickel beads coupled either to re-
combinant His-tau, which was phosphorylated, or to a dephospho-
rylated control. Considerably larger amounts of EAAT2 were
precipitated by p-tau than by dephosphorylated tau in all cases,
suggesting that EAAT2 preferentially interacted with p-tau com-
pared to dephosphorylated tau (Fig. 3A). The same amount of re-
combinant p-tau precipitated larger amounts of EAAT2 from AD,
PSP, and CBD brains than from normal brains (Fig. 3B). These re-
sults suggest that p-tau more preferentially associates with EAAT2
in tauopathic brains than normal brains.
Interaction of EAAT2 with p-tau suggested that EAAT2 may
localize in NFTs. In the midtemporal cortex, EAAT2 labeling oc-
curred in large numbers of neuronal NFTs in all AD brains
(Fig. 4A, B, and E), and in glial NFTs in PSP (Fig. 4C) and CBD brains
(Fig. 4D). There was weak staining of glia and no obvious staining
of neurons except for NFTs in AD, PSP, and CBD cases when thesamples were incubated with 70% formic acid. HS5 weakly stained
ordinarily expressed glial EAAT2 but not NFTs when slides were
incubated without 70% formic acid. Confocal microscopic examin-
ations showed that EAAT2 was partially colocalized with p-tau,
which was recognized by AT8 in NFTs of AD, PSP, and CBD brains
(Fig. 4F–Q).
Immunoblots showed the expected serial extraction of tau with
tau immunoreactivity in the sarkosyl-insoluble/formic acid-solu-
ble fraction in AD patients but not in controls (Fig. 5A). Remark-
ably, EAAT2 and high-molecular-weight EAAT2 were also present
in this fraction (Fig. 5A). EAAT2 was present in this fraction only
in AD, PSP, and CBD brains (Fig. 5B).4. Discussion
We have shown that EAAT2 interacts with p-tau in biochemical
and histochemical studies. Immunoprecipitation studies indicated
that EAAT2 preferentially associated with p-tau compared to
dephosphorylated tau. A pull-down assay using recombinant tau
or p-tau revealed that p-tau preferentially combined with EAAT2
from AD, PSP, or CBD brains compared to controls. Immunohisto-
chemical studies showed that not only neuronal EAAT2 in AD
brains but glial EAAT2 in PSP and CBD brains also colocalized with
p-tau in NFTs. This suggests that EAAT2 may have been caught up
with p-tau as tangles formed. Furthermore, we found high-molec-
ular-weight EAAT2 in the sarkosyl-insoluble fraction. This suggests
that EAAT2 may be oligomerized such as a-synuclein [15] and b-
amyloid [16], which are major components of inclusions in neuro-
degenerative disorders.
EAATs are essential proteins for glutamate and aspartate up-
take from the synaptic cleft into glias and neurons [17]. Several
EAATs have been isolated and characterized [18]. EAAT1 is pri-
marily localized in glia of the cerebellum and retina. EAAT2 is
speciﬁcally located on astrocytes in non-diseased brains and is
quantitatively dominant in the cortex [19]. EAAT2 is responsible
for a majority of glutamate clearance in the adult forebrain [18].
A link among glutamate transporter dysfunction, increased extra-
cellular glutamate levels, and the onset of excitotoxic neuronal
damage has been established in AD and other neurodegenerative
Fig. 4. Immunohistochemical analysis of EAAT2 in tauopathic specimens. (A–E) Neuroﬁbrillary tangles (NFTs) in CA1 immunoreactive for EAAT2. Neuronal NFTs
immunoreactive for EAAT2 in patients with AD (A, B, 400) (E, 100). Glial NFTs immunoreactive for EAAT2 in patients with PSP (C) or CBD (D, 400). AD (F–K), PSP (L–N),
and CBD (O–Q) double-labeling for EAAT2 (F, I, L and O) (green) or p-tau (G, J, M and P) (red). Merged images (H, K, N and Q) show the colocalization of p-tau and EAAT2. There
is an overlap of the epitopes in some NFTs.
2198 K. Sasaki et al. / FEBS Letters 583 (2009) 2194–2200disorders [20]. Ablation of EAAT2 or glutamate transporter 1 (ro-
dent homolog, GLT1) in mice has a signiﬁcant effect on the
development of pathogenic conditions and neurodegeneration
[21]. The glial transport of excitatory amino acids in AD is deﬁ-
cient and the number of EAAT2-expressing cortical astrocytes is
decreased [22].
In AD cases, expression of a glutamate transporter not normally
found in neurons could imply that abnormal EAAT2 expressionprecedes and causes tangle formation in the affected neurons.
Pull-down assays with recombinant p-tau showed that EAAT2
not only from AD but also from PSP and CBD brains preferentially
interacted with p-tau. Thus, even physiologically expressed glial
EAAT2 may be pathologically modiﬁed and subsequently bind with
p-tau in pathological glia of PSP and CBD brains. This implies that
neuronal and glial dysregulation of glutamate transport is strongly
linked to the pathogenesis of tauopathies.
Fig. 5. Serial extractions of the temporal cortex were prepared from AD, PSP, CBD, and normal brains. (A) Preparation of supernatants and TBS-soluble, 1% Triton-X 100-
soluble, sarkosyl-soluble, and sarkosyl-insoluble fractions are described in the Methods section. (B) Anti-EAAT2 immunoblots of sarkosyl-insoluble fraction from
homogenates from AD, PSP, CBD, and normal brains.
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detected in NFT-bearing neurons but were not localized in NFTs
of AD patients by immunohistochemical studies. Our results
showed that EAAT2 is localized in NFTs. The difference between
our results and those of previous studies is because of the different
antibodies and immunohistochemical methods used. In our study,
NFTs were not stained with our EAAT2 antibody due to the absence
of using 70% formic acid to activate the antigens. Our EAAT2 anti-
body might be suitable for the detection of insoluble EAAT2 in
immunohistochemical studies.
We therefore conclude that glutamate transport is altered in
tauopathies with aberrant and physiological expression of EAAT2,
and speculate that these changes occur before, but are related to,
neuroﬁbrillary pathology. These ﬁndings strongly implicate gluta-
mate-mediated toxicity as an important mechanism in tauopathy-
related neurodegeneration.Acknowledgments
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